Potential molecular prognostic markers in head and neck squamous cell carcinomas

Harry Quon, F. F. Liu, B. J. Cummings

Research output: Contribution to journalArticle

Abstract

Background. Current management strategies for squamous cell carcinoma of the head and neck (HNSCC) rely on an understanding of the natural history of the disease, along with the use of prognostic factors to guide selection of appropriate treatment. However, it is recognized that tumor heterogeneity limits the reliable use of currently available prognostic markers. With the evolving understanding of the genetic and molecular basis of human malignancies, there has been much interest in determining whether specific molecular changes in HNSCC might guide treatment decisions. Methods. A literature review of potential molecular markers relevant to HNSCC was undertaken and evaluated. It is evident that the published information is promising but, oftentimes, limited by a scarcity of large, uniformly staged and treated patients, from which the value of novel molecular markers can be assessed. Results. On the basis of the review of more than 100 articles, some of the emerging molecular markers that might provide independent prognostic information include epidermal growth factor receptor (EGFR), transforming growth factor-α (TGF-α), cyclin D1, and p53. This review will discuss the current status of these molecular factors and consequent implications for novel therapeutic approaches for patients with HNSCC. Conclusion. With the evolving understanding that human malignancies have developed and progressed on the basis of accumulated molecular abnormalities, there is an existing body of work trying to determine whether such abnormalities can predict clinical behavior of HNSCC. Such studies have to be conducted rigorously to derive useful information. Nevertheless, the role of such molecular markers, and the possibility to exploit them for therapeutic gain, is already at the horizon.

Original languageEnglish (US)
Pages (from-to)147-159
Number of pages13
JournalHead and Neck
Volume23
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Neoplasms
Cyclin D1
Transforming Growth Factors
Therapeutics
Epidermal Growth Factor Receptor
Molecular Biology
Carcinoma, squamous cell of head and neck

Keywords

  • Cyclin D1
  • EGFR
  • Head/neck squamous cell carcinomas
  • p53
  • Prognostic factors
  • TGF-α

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Potential molecular prognostic markers in head and neck squamous cell carcinomas. / Quon, Harry; Liu, F. F.; Cummings, B. J.

In: Head and Neck, Vol. 23, No. 2, 2001, p. 147-159.

Research output: Contribution to journalArticle

Quon, Harry ; Liu, F. F. ; Cummings, B. J. / Potential molecular prognostic markers in head and neck squamous cell carcinomas. In: Head and Neck. 2001 ; Vol. 23, No. 2. pp. 147-159.
@article{85186dac0f894054b75b3ccac99546a7,
title = "Potential molecular prognostic markers in head and neck squamous cell carcinomas",
abstract = "Background. Current management strategies for squamous cell carcinoma of the head and neck (HNSCC) rely on an understanding of the natural history of the disease, along with the use of prognostic factors to guide selection of appropriate treatment. However, it is recognized that tumor heterogeneity limits the reliable use of currently available prognostic markers. With the evolving understanding of the genetic and molecular basis of human malignancies, there has been much interest in determining whether specific molecular changes in HNSCC might guide treatment decisions. Methods. A literature review of potential molecular markers relevant to HNSCC was undertaken and evaluated. It is evident that the published information is promising but, oftentimes, limited by a scarcity of large, uniformly staged and treated patients, from which the value of novel molecular markers can be assessed. Results. On the basis of the review of more than 100 articles, some of the emerging molecular markers that might provide independent prognostic information include epidermal growth factor receptor (EGFR), transforming growth factor-α (TGF-α), cyclin D1, and p53. This review will discuss the current status of these molecular factors and consequent implications for novel therapeutic approaches for patients with HNSCC. Conclusion. With the evolving understanding that human malignancies have developed and progressed on the basis of accumulated molecular abnormalities, there is an existing body of work trying to determine whether such abnormalities can predict clinical behavior of HNSCC. Such studies have to be conducted rigorously to derive useful information. Nevertheless, the role of such molecular markers, and the possibility to exploit them for therapeutic gain, is already at the horizon.",
keywords = "Cyclin D1, EGFR, Head/neck squamous cell carcinomas, p53, Prognostic factors, TGF-α",
author = "Harry Quon and Liu, {F. F.} and Cummings, {B. J.}",
year = "2001",
doi = "10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#",
language = "English (US)",
volume = "23",
pages = "147--159",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Potential molecular prognostic markers in head and neck squamous cell carcinomas

AU - Quon, Harry

AU - Liu, F. F.

AU - Cummings, B. J.

PY - 2001

Y1 - 2001

N2 - Background. Current management strategies for squamous cell carcinoma of the head and neck (HNSCC) rely on an understanding of the natural history of the disease, along with the use of prognostic factors to guide selection of appropriate treatment. However, it is recognized that tumor heterogeneity limits the reliable use of currently available prognostic markers. With the evolving understanding of the genetic and molecular basis of human malignancies, there has been much interest in determining whether specific molecular changes in HNSCC might guide treatment decisions. Methods. A literature review of potential molecular markers relevant to HNSCC was undertaken and evaluated. It is evident that the published information is promising but, oftentimes, limited by a scarcity of large, uniformly staged and treated patients, from which the value of novel molecular markers can be assessed. Results. On the basis of the review of more than 100 articles, some of the emerging molecular markers that might provide independent prognostic information include epidermal growth factor receptor (EGFR), transforming growth factor-α (TGF-α), cyclin D1, and p53. This review will discuss the current status of these molecular factors and consequent implications for novel therapeutic approaches for patients with HNSCC. Conclusion. With the evolving understanding that human malignancies have developed and progressed on the basis of accumulated molecular abnormalities, there is an existing body of work trying to determine whether such abnormalities can predict clinical behavior of HNSCC. Such studies have to be conducted rigorously to derive useful information. Nevertheless, the role of such molecular markers, and the possibility to exploit them for therapeutic gain, is already at the horizon.

AB - Background. Current management strategies for squamous cell carcinoma of the head and neck (HNSCC) rely on an understanding of the natural history of the disease, along with the use of prognostic factors to guide selection of appropriate treatment. However, it is recognized that tumor heterogeneity limits the reliable use of currently available prognostic markers. With the evolving understanding of the genetic and molecular basis of human malignancies, there has been much interest in determining whether specific molecular changes in HNSCC might guide treatment decisions. Methods. A literature review of potential molecular markers relevant to HNSCC was undertaken and evaluated. It is evident that the published information is promising but, oftentimes, limited by a scarcity of large, uniformly staged and treated patients, from which the value of novel molecular markers can be assessed. Results. On the basis of the review of more than 100 articles, some of the emerging molecular markers that might provide independent prognostic information include epidermal growth factor receptor (EGFR), transforming growth factor-α (TGF-α), cyclin D1, and p53. This review will discuss the current status of these molecular factors and consequent implications for novel therapeutic approaches for patients with HNSCC. Conclusion. With the evolving understanding that human malignancies have developed and progressed on the basis of accumulated molecular abnormalities, there is an existing body of work trying to determine whether such abnormalities can predict clinical behavior of HNSCC. Such studies have to be conducted rigorously to derive useful information. Nevertheless, the role of such molecular markers, and the possibility to exploit them for therapeutic gain, is already at the horizon.

KW - Cyclin D1

KW - EGFR

KW - Head/neck squamous cell carcinomas

KW - p53

KW - Prognostic factors

KW - TGF-α

UR - http://www.scopus.com/inward/record.url?scp=0035176636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035176636&partnerID=8YFLogxK

U2 - 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#

DO - 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#

M3 - Article

C2 - 11303632

AN - SCOPUS:0035176636

VL - 23

SP - 147

EP - 159

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 2

ER -